Xcell Biosciences is a next-generation development and manufacturing platform for enhanced cell therapy performance.
Xcell Biosciences is a San Francisco-based life science start-up company that is developing novel and disruptive systems for cell therapy development and production. Their proprietary technology enables fine control of primary cell phenotype and function, enabling an entirely new capability for optimizing efficacy and persistence of immune cell therapies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 19, 2022 | Series B | $27.50M | 1 | — | — | Detail |